Related references
Note: Only part of the references are listed.Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy
Mattias Mandorfer et al.
HEPATOLOGY (2020)
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
Christopher L. Bowlus et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Agustin Albillos et al.
JOURNAL OF HEPATOLOGY (2020)
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals
Monica Pons et al.
JOURNAL OF HEPATOLOGY (2020)
Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis
Scott A. McDonald et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani et al.
GASTROENTEROLOGY (2020)
Albumin in decompensated cirrhosis: new concepts and perspectives
Mauro Bernardi et al.
GUT (2020)
Cirrhosis as new indication for statins
Jaime Bosch et al.
GUT (2020)
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
Guadalupe Garcia-Tsao et al.
JOURNAL OF HEPATOLOGY (2020)
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis
Jasmohan S. Bajaj et al.
JOURNAL OF HEPATOLOGY (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis
Cristina Diez et al.
CLINICAL INFECTIOUS DISEASES (2020)
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
Kris Kowdley et al.
JOURNAL OF HEPATOLOGY (2020)
Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis
Yuly P. Mendoza et al.
DIGESTIVE AND LIVER DISEASE (2020)
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension
Sabela Lens et al.
JOURNAL OF HEPATOLOGY (2020)
Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review
Mattias Mandorfer et al.
SEMINARS IN LIVER DISEASE (2020)
Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies
Georg Semmler et al.
JOURNAL OF HEPATOLOGY (2020)
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2019)
Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
Neil D. Shah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
Dominique Thabut et al.
GASTROENTEROLOGY (2019)
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial
Candid Villanueva et al.
LANCET (2019)
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
Arun J. Sanyal et al.
HEPATOLOGY (2019)
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
Maren H. Harms et al.
JOURNAL OF HEPATOLOGY (2019)
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Michael Trauner et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Gut-liver axis signaling in portal hypertension
Benedikt Simbrunner et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Michael Trauner et al.
HEPATOLOGY (2019)
Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
Juan G. Abraldes et al.
HEPATOLOGY (2019)
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
Gideon M. Hirschfield et al.
JOURNAL OF HEPATOLOGY (2019)
Hepatic microcirculation and mechanisms of portal hypertension
Jordi Gracia-Sancho et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Anticoagulation in the cirrhotic patient
Laura Turco et al.
JHEP REPORTS (2019)
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study
R. Schwarzer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity
M. Mandorfer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study
Saptarshi Bishnu et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2018)
A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis
Laurent Spahr et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2018)
People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol
Stephen R. Atkinson et al.
HEPATOLOGY (2018)
Clinical states of cirrhosis and competing risks
Gennaro D'Amico et al.
JOURNAL OF HEPATOLOGY (2018)
Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis
Laura Turco et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
JOURNAL OF HEPATOLOGY (2018)
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C. Corpechot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease
P. Schwabl et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Prevention of progression from small to large varices: are we there yet? An updated meta-analysis
Mattias Mandorfer et al.
GUT (2017)
Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2017)
Effects of an Intensive Lifestyle Intervention Program on Portal Hypertension in Patients With Cirrhosis and Obesity: The SportDiet Study
Annalisa Berzigotti et al.
HEPATOLOGY (2017)
Long-Term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis
Sumeyye Samur et al.
HEPATOLOGY (2017)
Main Drivers of Outcome Differ Between Short Term and Long Term in Severe Alcoholic Hepatitis: A Prospective Study
Alexandre Louvet et al.
HEPATOLOGY (2017)
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Peter Fickert et al.
JOURNAL OF HEPATOLOGY (2017)
Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis
Stephen R. Atkinson et al.
JOURNAL OF HEPATOLOGY (2017)
Beta adrenergic blockade and decompensated cirrhosis
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2017)
Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease
Carolin Lackner et al.
JOURNAL OF HEPATOLOGY (2017)
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension
N. Afdhal et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis
Rebecca G. Kim et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Beta blockers and cirrhosis, 2016
Mattias Mandorfer et al.
DIGESTIVE AND LIVER DISEASE (2017)
Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
A. C. Cheung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Development of hyperdynamic circulation and response to -blockers in compensated cirrhosis with portal hypertension
Candid Villanueva et al.
HEPATOLOGY (2016)
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension
Vito Di Marco et al.
GASTROENTEROLOGY (2016)
Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis
Juan G. Abraldes et al.
GASTROENTEROLOGY (2016)
Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension
Mattias Mandorfer et al.
JOURNAL OF HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses
M. Mandorfer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy
Sabela Lens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial
Priscila Pollo-Flores et al.
DIGESTIVE AND LIVER DISEASE (2015)
Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow
Emina Halilbasic et al.
DIGESTIVE DISEASES (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension
Roberto de Franchis
JOURNAL OF HEPATOLOGY (2015)
Severe hepatic injury associated with different statins in patients with chronic liver disease: A nationwide population-based cohort study
Chia-Hsuin Chang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure
Gautam Mehta et al.
LIVER INTERNATIONAL (2015)
Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis
E. Sinagra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients
G. D'Amico et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta-analysis
Yan-Di Xie et al.
HEPATOLOGY RESEARCH (2014)
Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease
Steven Masson et al.
LIVER INTERNATIONAL (2014)
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
Thomas Reiberger et al.
GUT (2013)
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2013)
The burden of liver disease in Europe: A review of available epidemiological data
Martin Blachier et al.
JOURNAL OF HEPATOLOGY (2013)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin
Thomas Reiberger et al.
ANTIVIRAL THERAPY (2012)
Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding
Salvador Augustin et al.
HEPATOLOGY (2012)
Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection
Thomas Reiberger et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center
Barbara Hoeroldt et al.
GASTROENTEROLOGY (2011)
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C
Timothy R. Morgan et al.
HEPATOLOGY (2010)
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis
Ana-Carolina Cardoso et al.
JOURNAL OF HEPATOLOGY (2010)
Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial
Juan G. Abraldes et al.
GASTROENTEROLOGY (2009)
Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension
Spilios Manolakopoulos et al.
JOURNAL OF HEPATOLOGY (2009)
Portal Hypertension and Primary Biliary Cirrhosis: Effect of Long-Term Ursodeoxycholic Acid Treatment
Pierre-Michel Huet et al.
GASTROENTEROLOGY (2008)
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
Bart J. Veldt et al.
ANNALS OF INTERNAL MEDICINE (2007)
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis
Cristina Ripoll et al.
GASTROENTEROLOGY (2007)
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
Savino Bruno et al.
HEPATOLOGY (2007)
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis
RJ Groszmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Lamivudine for patients with chronic hepatitis B and advanced liver disease
YF Liaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis
C Villanueva et al.
JOURNAL OF HEPATOLOGY (2004)
Share Paper
